S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
Algeria's government pushes staples to subsidized markets to stave off Ramadan shortages
How major US stock indexes fared Thursday, 3/28/2024
NASDAQ:ELVN

Enliven Therapeutics (ELVN) Stock Price, News & Analysis

$17.59
-1.04 (-5.58%)
(As of 03/28/2024 ET)
Today's Range
$17.36
$18.69
50-Day Range
$11.54
$19.21
52-Week Range
$9.80
$24.22
Volume
196,400 shs
Average Volume
157,752 shs
Market Capitalization
$724.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Enliven Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
100.0% Downside
$0.00 Price Target
Short Interest
Bearish
20.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.71mentions of Enliven Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
Selling Shares
$8.98 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.14) to ($2.83) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.09 out of 5 stars

Medical Sector

586th out of 939 stocks

Pharmaceutical Preparations Industry

278th out of 441 stocks

ELVN stock logo

About Enliven Therapeutics Stock (NASDAQ:ELVN)

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. Enliven Therapeutics, Inc. is headquartered in Boulder, Colorado.

ELVN Stock Price History

ELVN Stock News Headlines

4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Enliven Therapeutics (NASDAQ:ELVN) Shares Gap Up to $12.64
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
TD Cowen Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)
ELVN Mar 2024 20.000 call
Enliven Therapeutics GAAP EPS of -$0.51
Enliven Therapeutics Inc ELVN
See More Headlines
Receive ELVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ELVN
Fax
N/A
Employees
44
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$27.00
High Stock Price Target
$27.00
Low Stock Price Target
$27.00
Potential Upside/Downside
+53.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-71,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.97 per share

Miscellaneous

Free Float
22,330,000
Market Cap
$724.71 million
Optionable
Optionable
Beta
1.05
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Samuel S. Kintz M.B.A. (Age 38)
    Co-Founder, CEO, Secretary & Director
    Comp: $597k
  • Mr. Benjamin Hohl (Age 35)
    CFO & Head of Corporate Development
    Comp: $488.5k
  • Dr. Helen Louise Collins M.D. (Age 61)
    Chief Medical Officer
    Comp: $558k
  • Dr. Joseph P. Lyssikatos Ph.D. (Age 59)
    Co-Founder, Chief Scientific Officer & Directors
  • Mr. Anish Patel Pharm.D. (Age 44)
    Co-Founder & COO
  • Dr. Galya D. Blachman Esq. (Age 47)
    Ph.D., Chief Legal Officer & Head of Business Development

ELVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Enliven Therapeutics stock right now?

0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last year. There are currently for the stock. The consensus among Wall Street analysts is that investors should "n/a" ELVN shares.
View ELVN analyst ratings
or view top-rated stocks.

What is Enliven Therapeutics' stock price target for 2024?

0 brokers have issued twelve-month price targets for Enliven Therapeutics' stock. Their ELVN share price targets range from $10,000,000.00 to $0.00. On average, they predict the company's stock price to reach $0.00 in the next twelve months. This suggests that the stock has a possible downside of 100.0%.
View analysts price targets for ELVN
or view top-rated stocks among Wall Street analysts.

How have ELVN shares performed in 2024?

Enliven Therapeutics' stock was trading at $13.84 at the beginning of the year. Since then, ELVN shares have increased by 27.1% and is now trading at $17.59.
View the best growth stocks for 2024 here
.

When is Enliven Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our ELVN earnings forecast
.

Who are Enliven Therapeutics' major shareholders?

Enliven Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Citadel Advisors LLC (5.81%), Vanguard Group Inc. (2.99%), Vanguard Group Inc. (2.99%), Northern Trust Corp (0.55%), Charles Schwab Investment Management Inc. (0.38%) and Barclays PLC (0.10%). Insiders that own company stock include 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Richard A Heyman and Samuel Kintz.
View institutional ownership trends
.

How do I buy shares of Enliven Therapeutics?

Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ELVN) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners